clinical trial · NCT05854784
Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)
Variegate PorphyriaAfamelanotide 16 MG
brief summary
The primary objective is to evaluate the impact of afamelanotide on the severity of skin disease in patients with Variegate Porphyria (VP). The secondary objectives are to evaluate the safety and tolerability of afamelanotide in patients with VP and evaluate the impact of afamelanotide on the quality of life of patients with VP.
started
Mar 28, 2023
primary completion
Dec 28, 2023
completion
Dec 28, 2023
last updated
Apr 27, 2025
official title
Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)-Related Skin Disease.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol